Benign hereditary telangiectasia is an inherited condition that causes dilated blood vessels on your skin and lips. Unlike other similar conditions, it does not cause any systemic symptoms.

Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

A strong family history of brain aneurysms significantly increases a person’s likelihood of developing one — often earlier in life. Medical experts are increasingly urging individuals with such a ...

for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the European Medicines Agency (EMA) provided a positive opinion for ODD, confirming that DIAG723 meets the criteria ...

Pomalidomide, a cancer medication, has been revealed in a clinical trial to be safe and efficacious in treating hereditary hemorrhagic telangiectasia (HHT). This rare bleeding disorder affects ...

Significant reduction seen in epistaxis severity with pomalidomide treatment for patients with HHT. HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide ...

Review article Hereditary hemorrhagic telangiectasia (Osler’s disease) Systemic, interdisciplinary, relatively common—and often missed Dtsch Arztebl Int 2024; 121: 601-7.DOI: 10.3238/arztebl ...

telangiectasia can also be associated with certain medical conditions, including rosacea, scleroderma, liver disease, and hereditary hemorrhagic telangiectasia (HHT), amongst others. Recognizing ...

Benign hereditary telangiectasia (BHT) occurs when small thread veins have dilated and are visible on the skin and lips. On dark skin, these veins may appear purple. On light skin, they may look red.

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia ...